Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?

Over the last two decades there have been meaningful developments on biomarkers of neurodegenerative diseases, extensively (but not solely) focusing on their proteinopathic nature. Accordingly, in Alzheimer's disease determination of levels of total and phosphorylated tau (τ and p-τ, usually p-...

Full description

Bibliographic Details
Authors: Painous Martí, Cèlia, Fernández, Manel, Pérez, Jesica, de Mena, Lorena, Cámara, Ana, Compta, Yaroslau
Format: article
Status:Versión aceptada para publicación
Publication Date:2024
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/218973
Online Access:https://hdl.handle.net/2445/218973
Access Level:Open access
Keyword:Marcadors bioquímics
Diagnòstic
Malaltia de Parkinson
Líquid cefalorraquidi
Biochemical markers
Diagnosis
Parkinson's disease
Cerebrospinal fluid
id ES_0aac7b4c8da0510190cfa2cd819bcad7
oai_identifier_str oai:diposit.ub.edu:2445/218973
network_acronym_str ES
network_name_str España
repository_id_str
spelling Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?Painous Martí, CèliaFernández, ManelPérez, Jesicade Mena, LorenaCámara, AnaCompta, YaroslauMarcadors bioquímicsDiagnòsticMalaltia de ParkinsonLíquid cefalorraquidiBiochemical markersDiagnosisParkinson's diseaseCerebrospinal fluidOver the last two decades there have been meaningful developments on biomarkers of neurodegenerative diseases, extensively (but not solely) focusing on their proteinopathic nature. Accordingly, in Alzheimer's disease determination of levels of total and phosphorylated tau (τ and p-τ, usually p-τ181) along with amyloid-beta1-42 (Aβ1-42) by immunodetection in cerebrospinal fluid (CSF) and currently even in peripheral blood, have been widely accepted and introduced to routine diagnosis. In the case of Parkinson's disease, α-synuclein as a potential biomarker (both for diagnosis and progression tracking) has proved more elusive under the immunodetection approach. In recent years, the emergence of the so-called seed amplification assays is proving to be a game-changer, with mounting evidence under different technical approaches and using a variety of biofluids or tissues, yielding promising diagnostic accuracies. Currently the least invasive but at once more reliable source of biosamples and techniques are being sought. Here we overview these advances.Elsevier B.V.2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/218973Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1016/j.parkreldis.2023.105968Parkinsonism & Related Disorders, 2024, vol. 121https://doi.org/10.1016/j.parkreldis.2023.105968cc-by-nc-nd (c) Elsevier B.V., 2024http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2189732026-05-27T06:46:51Z
dc.title.none.fl_str_mv Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
title Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
spellingShingle Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
Painous Martí, Cèlia
Marcadors bioquímics
Diagnòstic
Malaltia de Parkinson
Líquid cefalorraquidi
Biochemical markers
Diagnosis
Parkinson's disease
Cerebrospinal fluid
title_short Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
title_full Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
title_fullStr Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
title_full_unstemmed Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
title_sort Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?
dc.creator.none.fl_str_mv Painous Martí, Cèlia
Fernández, Manel
Pérez, Jesica
de Mena, Lorena
Cámara, Ana
Compta, Yaroslau
author Painous Martí, Cèlia
author_facet Painous Martí, Cèlia
Fernández, Manel
Pérez, Jesica
de Mena, Lorena
Cámara, Ana
Compta, Yaroslau
author_role author
author2 Fernández, Manel
Pérez, Jesica
de Mena, Lorena
Cámara, Ana
Compta, Yaroslau
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Marcadors bioquímics
Diagnòstic
Malaltia de Parkinson
Líquid cefalorraquidi
Biochemical markers
Diagnosis
Parkinson's disease
Cerebrospinal fluid
topic Marcadors bioquímics
Diagnòstic
Malaltia de Parkinson
Líquid cefalorraquidi
Biochemical markers
Diagnosis
Parkinson's disease
Cerebrospinal fluid
description Over the last two decades there have been meaningful developments on biomarkers of neurodegenerative diseases, extensively (but not solely) focusing on their proteinopathic nature. Accordingly, in Alzheimer's disease determination of levels of total and phosphorylated tau (τ and p-τ, usually p-τ181) along with amyloid-beta1-42 (Aβ1-42) by immunodetection in cerebrospinal fluid (CSF) and currently even in peripheral blood, have been widely accepted and introduced to routine diagnosis. In the case of Parkinson's disease, α-synuclein as a potential biomarker (both for diagnosis and progression tracking) has proved more elusive under the immunodetection approach. In recent years, the emergence of the so-called seed amplification assays is proving to be a game-changer, with mounting evidence under different technical approaches and using a variety of biofluids or tissues, yielding promising diagnostic accuracies. Currently the least invasive but at once more reliable source of biosamples and techniques are being sought. Here we overview these advances.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/218973
url https://hdl.handle.net/2445/218973
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1016/j.parkreldis.2023.105968
Parkinsonism & Related Disorders, 2024, vol. 121
https://doi.org/10.1016/j.parkreldis.2023.105968
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Elsevier B.V., 2024
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Elsevier B.V., 2024
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403177388867584
score 15,811543

Similar Items